Glycemic targets: what is the evidence?

Authors

Silvio Inzucchi, Department of Endocrinology, Yale University School of Medicine, New Haven, CT; Medical Director, Yale Diabetes Center, Yale-New Haven Hospital, New Haven, CT. Electronic address: silvio.inzucchi@yale.edu.
Sachin Majumdar, Department of Endocrinology, Yale University School of Medicine, New Haven, CT; Section of Endocrinology, Bridgeport Hospital, Yale New Haven Health System, Bridgeport, CT.Follow

Document Type

Article

Publication Title

The Medical clinics of North America

Abstract

Hyperglycemia is the unifying metabolic abnormality for all forms of diabetes mellitus, forming the basis for its diagnosis and treatment. The strong epidemiologic associations between hyperglycemia and the complications of diabetes have given rise to the glucose hypothesis-that the complications of diabetes are caused by hyperglycemia and that they can be prevented by normalizing glucose levels. Herein the authors review the epidemiologic relationships between hyperglycemia and the complications of diabetes, the major trials of glucose lowering, and the extent to which the glucose hypothesis is supported by these studies and how this information can be translated into clinical practice.

First Page

47

Last Page

67

DOI

10.1016/j.mcna.2014.08.018

Publication Date

1-1-2015

Recommended Citation

Inzucchi, Silvio and Majumdar, Sachin, "Glycemic targets: what is the evidence?" (2015). Internal Medicine. 228.
https://scholar.bridgeporthospital.org/internal_medicine/228

Identifier

25456643 (pubmed); 10.1016/j.mcna.2014.08.018 (doi); S0025-7125(14)00144-8 (pii)